0

2-Hydroxypropyl-β-cyclodextrin-modified SLN of Paclitaxel for Overcoming P-Glycoprotein Function in Multidrug-Resistant Breast Cancer Cells

Jong-Suep Baek, Cheong-Weon Cho

J Pharm Pharmacol. 2013 Jan;65(1):72-8.

PMID: 23215690

Abstract:

Objectives:
This study aimed to evaluate the potential of solid lipid nanoparticles (SLNs) of paclitaxel (PTX) modified with a 2-hydroxypropyl-β-cyclodextrin system to enhance cellular accumulation of PTX into p-glycoprotein (p-gp)-expressing cells.
Methods:
The PTX-loaded-SLNs consisted of lipid (stearic acid) and surfactants (lecithin and poloxamer 188) and were then modified with 2-hydroxypropyl-β-cyclodextrin by a sonication method.
Key findings:
In terms of cytotoxicity, PTX-loaded SLNs modified with 2-hydroxypropyl-β-cyclodextrin showed higher cytotoxicity than other formulations. In particular, the cellular uptake of PTX from PTX-loaded SLNs modified with 2-hydroxypropyl-β-cyclodextrin was about 5.8- and 1.5-fold higher than that from PTX solution and unmodified PTX-loaded SLNs in MCF-7/ADR cells, respectively. After a 4-h incubation, clear fluorescence images inside cells were observed over time. When PTX-loaded SLNs modified with 2-hydroxypropyl-β-cyclodextrin were incubated with MCF-7/ADR cells for 4 h, cellular uptake of PTX increased 1.7-fold versus that of PTX in the presence of verapamil.
Conclusions:
These results suggest that optimized SLNs modified with 2-hydroxypropyl-β-cyclodextrin may have potential as an oral drug delivery system for PTX.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP128446355 (2-Hydroxypropyl)-β-cyclodextrin (2-Hydroxypropyl)-β-cyclodextrin 128446-35-5 Price
qrcode

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x